409 related articles for article (PubMed ID: 18451251)
1. Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor.
Eto M; Kamiryo Y; Takeuchi A; Harano M; Tatsugami K; Harada M; Kiyoshima K; Hamaguchi M; Teshima T; Tsuneyoshi M; Yoshikai Y; Naito S
Clin Cancer Res; 2008 May; 14(9):2833-40. PubMed ID: 18451251
[TBL] [Abstract][Full Text] [Related]
2. Renal cancer treatment with low levels of mixed chimerism induced by nonmyeloablative regimen using cyclophosphamide in mice.
Harano M; Eto M; Iwai T; Tatsugami K; Kiyoshima K; Kamiryo Y; Tsuneyoshi M; Yoshikai Y; Naito S
Cancer Res; 2005 Nov; 65(21):10032-40. PubMed ID: 16267029
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic cell therapy from immunized donors with tumor antigen peptide enhances the antitumor effect after cyclophosphamide-using non-myeloablative allogeneic hematopoietic cell transplantation.
Hamaguchi M; Eto M; Kamiryo Y; Takeuchi A; Harano M; Tatsugami K; Teshima T; Harada M; Yoshikai Y; Naito S
Cancer Sci; 2009 Jan; 100(1):138-43. PubMed ID: 19037994
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide-using nonmyeloablative allogeneic cell therapy against renal cancer with a reduced risk of graft-versus-host disease.
Eto M; Harano M; Tatsugami K; Harada M; Kamiryo Y; Kiyoshima K; Hamaguchi M; Tsuneyoshi M; Yoshikai Y; Naito S
Clin Cancer Res; 2007 Feb; 13(3):1029-35. PubMed ID: 17289899
[TBL] [Abstract][Full Text] [Related]
7. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
[TBL] [Abstract][Full Text] [Related]
8. Renal cancer treatment with recipient lymphocyte infusion enhanced the antitumor effect of nonmyeloablative allogeneic stem cell transplantation.
Takeuchi A; Eto M; Tatsugami K; Yamada H; Yokomizo A; Shiota M; Itsumi M; Inokuchi J; Kiyoshima K; Dejima T; Imada K; Naito S; Yoshikai Y
Transpl Immunol; 2015 Mar; 32(2):131-9. PubMed ID: 25527449
[TBL] [Abstract][Full Text] [Related]
9. Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: extinction of graft-versus-leukemia effects after conversion to full donor chimerism.
Mapara MY; Kim YM; Marx J; Sykes M
Transplantation; 2003 Jul; 76(2):297-305. PubMed ID: 12883182
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of recipient leukocyte infusion as antitumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantation.
Saito TI; Rubio MT; Sykes M
Exp Hematol; 2006 Sep; 34(9):1271-7. PubMed ID: 16939820
[TBL] [Abstract][Full Text] [Related]
11. Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy.
Pan Y; Luo B; Sozen H; Kalscheuer H; Blazar BR; Sutherland DE; Hering BJ; Guo Z
Transplantation; 2003 Jul; 76(1):216-24. PubMed ID: 12865813
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease.
Ohashi M; Kobayashi A; Hara H; Miura Y; Yoshida K; Kushida M; Ikarashi Y; Mandai M; Kitajima M; Yoshida T; Aoki K
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2208-15. PubMed ID: 16609036
[TBL] [Abstract][Full Text] [Related]
13. Donor CD4 T cells are critical in allogeneic stem cell transplantation against murine solid tumor.
Kamiryo Y; Eto M; Yamada H; Yajima T; Harano M; Takeuchi A; Tatsugami K; Hamaguchi M; Naito S; Yoshikai Y
Cancer Res; 2009 Jun; 69(12):5151-8. PubMed ID: 19491277
[TBL] [Abstract][Full Text] [Related]
14. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.
Childs R; Chernoff A; Contentin N; Bahceci E; Schrump D; Leitman S; Read EJ; Tisdale J; Dunbar C; Linehan WM; Young NS; Barrett AJ
N Engl J Med; 2000 Sep; 343(11):750-8. PubMed ID: 10984562
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of late rather than early full-donor chimerism in patients with advanced lymphomas receiving nonmyeloablative allogeneic hematopoietic SCT.
Ting DT; Spitzer TR; Chaudhary A; Muzikansky A; Colby C; Power K; McAfee S; Ballen K; Attar E; Saidman SL; Preffer F; Sykes M; Dey BR
Bone Marrow Transplant; 2008 Sep; 42(5):329-35. PubMed ID: 18587439
[TBL] [Abstract][Full Text] [Related]
16. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
[TBL] [Abstract][Full Text] [Related]
17. Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease.
Yang I; Weiss L; Abdul-Hai A; Kasir J; Reich S; Slavin S
Cancer Res; 2005 Nov; 65(21):9735-40. PubMed ID: 16266994
[TBL] [Abstract][Full Text] [Related]
18. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors.
Demirer T; Barkholt L; Blaise D; Pedrazzoli P; Aglietta M; Carella AM; Bay JO; Arpaci F; Rosti G; Gurman G; Niederwieser D; Bregni M;
Nat Clin Pract Oncol; 2008 May; 5(5):256-67. PubMed ID: 18398414
[TBL] [Abstract][Full Text] [Related]
19. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
Du B; Li DP; Xu KL; Pan XY
Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
[TBL] [Abstract][Full Text] [Related]
20. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
